keyword
https://read.qxmd.com/read/38544813/revolutionizing-treatment-strategies-for-autoimmune-and-inflammatory-disorders-the-impact-of-dipeptidyl-peptidase-4-inhibitors
#1
REVIEW
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Naveed Nawaz, Sajida Maryam, Mansour S Alturki, Abdulaziz H Al Khzem, Kamel Metwally, Simona Cavalu, Saleh F Alqifari, Galal Yahya
DPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augmenting the breakdown of adenosine-an influential inhibitor of T cell proliferation...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38480622/a-comprehensive-review-on-potential-drug-drug-interactions-of-proton-pump-inhibitors-with-antidiabetic-drugs-metformin-and-dpp-4-inhibitors
#2
REVIEW
Jarin Tasnim, Najihah Mohd Hashim, Heh Choon Han
A drug interaction is a condition in which two or more drugs are taken at the same time. Type 2 diabetes mellitus is a significant contributor to polypharmacy. Proton pump inhibitors (PPIs) are often prescribed in combination with metformin or DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) or a combined dose of metformin and DPP-4 inhibitor to treat gastritis in diabetic patients. This review article mainly focused on evaluating the potential drug-drug interactions (DDIs) between PPIs (i...
March 2024: Cell Biochemistry and Function
https://read.qxmd.com/read/38471670/landscape-of-pharmacogenetic-variants-associated-with-non-insulin-antidiabetic-drugs-in-the-indian-population
#3
JOURNAL ARTICLE
Ambily Sivadas, S Sahana, Bani Jolly, Rahul C Bhoyar, Abhinav Jain, Disha Sharma, Mohamed Imran, Vigneshwar Senthivel, Mohit Kumar Divakar, Anushree Mishra, Arpita Mukhopadhyay, Greg Gibson, Km Venkat Narayan, Sridhar Sivasubbu, Vinod Scaria, Anura V Kurpad
INTRODUCTION: Genetic variants contribute to differential responses to non-insulin antidiabetic drugs (NIADs), and consequently to variable plasma glucose control. Optimal control of plasma glucose is paramount to minimizing type 2 diabetes-related long-term complications. India's distinct genetic architecture and its exploding burden of type 2 diabetes warrants a population-specific survey of NIAD-associated pharmacogenetic (PGx) variants. The recent availability of large-scale whole genomes from the Indian population provides a unique opportunity to generate a population-specific map of NIAD-associated PGx variants...
March 12, 2024: BMJ Open Diabetes Research & Care
https://read.qxmd.com/read/38448210/contact-allergy-to-olanzapine-and-saxagliptin-in-a-pharmaceutical-industrial-worker-a-case-report
#4
Huršidić Radulović Azra, Babić Željka, Macan Marija, Macan Jelena
No abstract text is available yet for this article.
March 6, 2024: Contact Dermatitis
https://read.qxmd.com/read/38412282/continuous-glucose-monitoring-profiles-and-health-outcomes-after-dapagliflozin-plus-saxagliptin-vs-insulin-glargine
#5
JOURNAL ARTICLE
Donald C Simonson, Marcia A Testa, Ella Ekholm, Maxwell Su, Tina Vilsbøll, Serge A Jabbour, Marcus Lind
CONTEXT: Glycemic variability and hypoglycemia during diabetes treatment may impact therapeutic effectiveness and safety, even when glycated hemoglobin (HbA1c) reduction is comparable between therapies. OBJECTIVE: We employed masked continuous glucose monitoring (CGM) during a randomized trial of dapagliflozin plus saxagliptin (DAPA+SAXA) vs insulin glargine (INS) to compare glucose variability and patient-reported outcomes (PROs). DESIGN: 24-week sub-study of a randomized, open-label, two-arm, parallel-group, phase 3b study...
February 27, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38399334/physiologically-based-pharmacokinetic-pbpk-modeling-to-predict-cyp3a-mediated-drug-interaction-between-saxagliptin-and-nicardipine-bridging-rat-to-human-extrapolation
#6
JOURNAL ARTICLE
Jeong-Min Lee, Jin-Ha Yoon, Han-Joo Maeng, Yu Chul Kim
The aim of this study was to predict the cytochrome P450 3A (CYP3A)-mediated drug-drug interactions (DDIs) between saxagliptin and nicardipine using a physiologically based pharmacokinetic (PBPK) model. Initially, in silico and in vitro parameters were gathered from experiments or the literature to construct PBPK models for each drug in rats. These models were integrated to predict the DDIs between saxagliptin, metabolized via CYP3A2, and nicardipine, exhibiting CYP3A inhibitory activity. The rat DDI PBPK model was completed by optimizing parameters using experimental rat plasma concentrations after co-administration of both drugs...
February 16, 2024: Pharmaceutics
https://read.qxmd.com/read/38376877/statement-of-retraction-saxagliptin-enhances-osteogenic-differentiation-in-mc3t3-e1-cells-dependent-on-the-activation-of-amp-activated-protein-kinase-%C3%AE-ampk%C3%AE-runt-related-transcription-factor-2-runx-2
#7
https://read.qxmd.com/read/38320507/trials-and-tribulations-the-challenges-of-clinical-trials-in-children
#8
EDITORIAL
Susan L Furth
In this issue of NEJM Evidence, we see the results of a randomized clinical trial of dapagliflozin or saxagliptin in pediatric type 2 diabetes (T2D). In children and adolescents with T2D, dapagliflozin achieved significant improvements in glycemia in the trial.1 In June 2023, following another pivotal trial, the U.S. Food and Drug Administration (FDA) approved empagliflozin and the combination of empagliflozin and metformin as additions to diet and exercise to improve blood sugar control in children 10 years and older with T2D...
December 2023: NEJM Evid
https://read.qxmd.com/read/38320500/dapagliflozin-or-saxagliptin-in-pediatric-type-2-diabetes
#9
JOURNAL ARTICLE
Naim Shehadeh, Timothy Barrett, Pietro Galassetti, Cecilia Karlsson, John Monyak, Nayyar Iqbal, William V Tamborlane
Dapagliflozin or Saxagliptin in Pediatric Type 2 DiabetesDapagliflozin (a sodium-glucose co-transporter-2 inhibitor) and saxagliptin (a dipeptidyl peptidase-4 inhibitor) have both been approved by the U.S. Food and Drug Administration for the treatment of type 2 diabetes in adults but not in children. In this randomized trial of 245 pediatric patients (10 to 17 years of age) with uncontrolled type 2 diabetes, dapagliflozin but not saxagliptin significantly reduced A1C compared with placebo.
December 2023: NEJM Evid
https://read.qxmd.com/read/38297915/saxagliptin-dapagliflozin-is-non-inferior-to-insulin-glargine-in-terms-of-%C3%AE-cell-function-in-subjects-with-latent-autoimmune-diabetes-in-adults-a-12-month-randomized-comparator-controlled-pilot-study
#10
JOURNAL ARTICLE
Ernesto Maddaloni, Anda M Naciu, Carmen Mignogna, Raffaele Galiero, Rocco Amendolara, Marta Fogolari, Chiara Satta, Chiara Serafini, Silvia Angeletti, Maria Gisella Cavallo, Efisio Cossu, Ferdinando Carlo Sasso, Raffaella Buzzetti, Paolo Pozzilli
AIM: To compare the efficacy and safety of saxagliptin/dapagliflozin and insulin glargine in people with latent autoimmune diabetes in adults (LADA). METHODS: In this phase 2b multicentre, open-label, comparator-controlled, parallel-group, non-inferiority study, we randomly assigned 33 people with LADA who had a fasting C-peptide concentration ≥0.2 nmol/L (0.6 ng/mL) to receive 1-year daily treatment with either the combination of saxagliptin (5 mg) plus dapagliflozin (10 mg) or insulin glargine (starting dose: 10 IU), both on top of metformin...
January 31, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38260948/insights-from-in-silico-exploration-of-major-curcumin-analogs-targeting-human-dipeptidyl-peptidase-iv
#11
JOURNAL ARTICLE
Miah Roney, Amit Dubey, Abdul Rashid Issahaku, Md Nazim Uddin, Aisha Tufail, Anke Wilhelm, Normaiza Binti Zamri, Mohd Fadhlizil Fasihi Mohd Aluwi
The goal of this work is to use a variety of in-silico techniques to identify anti-diabetic agents against DPP-IV enzyme from five main curcumin analogues. To produce the successful molecules, five main curcumin analogues were docked into the active site of DPP-IV enzyme. In comparison to the control molecule (Saxagliptin, -6.9 kcal/mol), all the compounds have the highest binding affinity (-7.6 to -7.7 kcal/mol) for the DPP-IV enzyme. These compounds underwent further testing for studies on drug-likeness, pharmacokinetics, and acute toxicity to see the efficacy and safety of compounds...
January 23, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38258116/evaluation-of-the-drug-induced-liver-injury-potential-of-saxagliptin-through-reactive-metabolite-identification-in-rats
#12
JOURNAL ARTICLE
Ki-Young Kim, Yeo-Jin Jeong, So-Young Park, Eun-Ji Park, Ji-Hyeon Jeon, Im-Sook Song, Kwang-Hyeon Liu
A liver injury was recently reported for saxagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor. However, the underlying mechanisms of saxagliptin-induced liver injury remain unknown. This study aimed to evaluate whether saxagliptin, a potent and selective DPP-4 inhibitor that is globally used for treating type 2 diabetes mellitus, binds to the nucleophiles in vitro. Four DPP-4 inhibitors, including vildagliptin, were evaluated for comparison. Only saxagliptin and vildagliptin, which both contain a cyanopyrrolidine group, quickly reacted with L-cysteine to enzyme-independently produce thiazolinic acid metabolites...
January 13, 2024: Pharmaceutics
https://read.qxmd.com/read/38243349/comparative-therapeutic-effect-of-single-combined-administration-of-saxagliptin-metformin-and-intranasal-insulin-on-dexamethasone-induced-insulin-resistance-in-albino-wistar-rat-model
#13
JOURNAL ARTICLE
Jephtah Oche, Olufunke Olorundare, Saheed Afolabi, Mary Ologe, Anoka Njan, Olatunde Akanbi
Glucocorticoids have therapeutic benefits in the management of several inflammatory and immunological disorders. Despite these medicinal effects, they have the drawback of causing metabolic disorders such as hyperglycemia, insulin resistance etc., which is known to be a key indicator of metabolic syndrome. Metabolic syndrome is a major predisposing factor to type 2 diabetes mellitus and cardiomyopathy. This study was designed to compare and evaluate the effects of saxagliptin, metformin and intranasal insulin (when used singly or in combination) on dexamethasone induced insulin resistance...
June 30, 2023: Nigerian Journal of Physiological Sciences: Official Publication of the Physiological Society of Nigeria
https://read.qxmd.com/read/38137521/the-safety-and-efficacy-of-combining-saxagliptin-and-pioglitazone-therapy-in-streptozocin-induced-diabetic-rats
#14
JOURNAL ARTICLE
Ahmed Mohamed Othman, Ibrahim Ashour Ibrahim, Samy M Saleh, Dina M Abo-Elmatty, Noha M Mesbah, Asmaa R Abdel-Hamed
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic progressive disease due to insulin resistance. Oxidative stress complicates the etiology of T2DM. Saxagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, while Pioglitazone is a thiazolidinedione insulin sensitizer. This study aimed to assess the effect of Saxagliptin and Pioglitazone monotherapy and combination therapy on the biochemical and biological parameters in streptozotocin (STZ)-induced diabetic rats. METHODS: The study included thirty-five male albino rats...
December 13, 2023: Biomedicines
https://read.qxmd.com/read/38063096/saxagliptin-reduces-the-injury-of-alzheimer-s-disease-cell-model-by-down-regulating-the-expression-of-mir-483-5p
#15
JOURNAL ARTICLE
Yiting Hou, Lihua Dong, Lihua Cao
This study aimed to investigate the effect of saxagliptin on the injury of Alzheimer's disease (AD) cell model and its possible mechanism. SK-N-SH cells were cultured in vitro and divided into CON group, AD group, AD+L-SAX group, AD+M-SAX group, AD+H-SAX group, AD+anti-miR-NC group, AD+anti-miR-483-5p group, AD+SAX+miR-NC group and AD+SAX+miR-483-5p group. Then the levels of MDA, SOD and GSH-Px in each group were detected by ELISA method; cell apoptosis was detected by flow cytometry; the protein expression levels of Bax and Bcl-2 were detected by Western Blot; the expression level of miR-483-5p was detected by RT-qPCR...
November 30, 2023: Cellular and Molecular Biology
https://read.qxmd.com/read/38017482/effects-of-dapagliflozin-and-dapagliflozin-saxagliptin-on-erythropoiesis-iron-and-inflammation-markers-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-data-from-the-delight-trial
#16
RANDOMIZED CONTROLLED TRIAL
Akihiko Koshino, Brendon L Neuen, Niels Jongs, Carol Pollock, Peter J Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J L Heerspink
BACKGROUND: This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. METHODS: Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin and saxagliptin, or placebo. We measured hemoglobin, iron markers (serum iron, transferrin saturation, and ferritin), plasma erythropoietin, and inflammatory markers (urinary MCP-1 and urinary/serum IL-6) at baseline and week 24...
November 28, 2023: Cardiovascular Diabetology
https://read.qxmd.com/read/37973297/saxagliptin-a-selective-dipeptidyl-peptidase-4-inhibitor-alleviates-somatic-cell-aneugenicity-and-clastogenicity-in-diabetic-mice
#17
JOURNAL ARTICLE
Sabry M Attia, Sheikh F Ahmad, Ahmed Nadeem, Mohamed S M Attia, Mushtaq A Ansari, Abdelkader E Ashour, Norah A Albekairi, Mohammed A Al-Hamamah, Ali A Alshamrani, Saleh A Bakheet
Diabetes-related complications are becoming increasingly common as the global prevalence of diabetes increases. Diabetes is also linked to a high risk of developing cancer. This raises the question of whether cancer vulnerability is caused by diabetes itself or the use of antidiabetic drugs. Chromosomal instability, a source of genetic modification involving either an altered chromosomal number or structure, is a hallmark of cancer. Saxagliptin has been approved by the FDA for diabetes treatment. However, the detailed in vivo effects of prolonged saxagliptin treatment on chromosomal instability have not yet been reported...
2023: Mutation Research. Genetic Toxicology and Environmental Mutagenesis
https://read.qxmd.com/read/37893048/impacts-of-the-dpp-4-inhibitor-saxagliptin-and-sglt-2-inhibitor-dapagliflozin-on-the-gonads-of-diabetic-mice
#18
JOURNAL ARTICLE
Ali A Alshamrani, Mohammed A Al-Hamamah, Norah A Albekairi, Mohamed S M Attia, Sheikh F Ahmad, Mohammed A Assiri, Mushtaq A Ansari, Ahmed Nadeem, Saleh A Bakheet, Wael A Alanazi, Sabry M Attia
Diabetes mellitus is a metabolic disease that can cause systemic problems, including testicular dysfunction. Several diabetes medications have demonstrated potential adverse effects on the male reproductive system; however, the effects of saxagliptin and dapagliflozin have not been sufficiently examined. This investigation studied the impacts of saxagliptin and dapagliflozin treatments on the gonads in a male mouse model of diabetes. Testicular disturbances were assessed by sperm DNA damage, diakinesis-metaphase I chromosome examination, and spermiogram analysis...
September 29, 2023: Biomedicines
https://read.qxmd.com/read/37691025/relationship-between-saxagliptin-use-and-left-ventricular-diastolic-function-assessed-by-cardiac-mri
#19
JOURNAL ARTICLE
Kathy C K Wong, Huda S Ismail, Kim A Connelly, Subodh Verma, Ming-Yen Ng, Djeven P Deva, Andrew T Yan, Laura Jimenez-Juan
AIMS: Type 2 diabetes mellitus (T2DM) increases the risk of major cardiovascular events. In SAVOR-TIMI53 trial, the excess heart failure (HF) hospitalization among patients with T2DM in the saxagliptin group remains poorly understood. Our aim was to evaluate left ventricular (LV) diastolic function after 6 months of saxagliptin treatment using cardiac magnetic resonance imaging (CMR) in patients with T2DM. METHODS: In this prospective study, 16 T2DM patients without HF were prescribed saxagliptin as part of routine guideline-directed management...
September 10, 2023: Acta Diabetologica
https://read.qxmd.com/read/37685355/effects-of-incretin-based-treatment-on-the-diastolic-dys-function-in-patients-with-uncontrolled-type-2-diabetes-mellitus-a-prospective-study-with-1-year-follow-up
#20
JOURNAL ARTICLE
Elena-Daniela Grigorescu, Cristina-Mihaela Lăcătușu, Mariana Floria, Georgiana-Diana Cazac, Alina Onofriescu, Livia-Amira Sauciuc, Alexandr Ceasovschih, Ioana Crețu, Bogdan-Mircea Mihai, Laurențiu Șorodoc
Left ventricular diastolic dysfunction (DD) is a subclinical cardiac abnormality in patients with type 2 diabetes mellitus (T2DM) that can progress to heart failure (HF) and increase cardiovascular risk. This prospective study evaluated the DD in T2DM patients without atherosclerotic cardiovascular disease after one year of incretin-based drugs added to standard treatment. Of the 138 enrolled patients (49.30% male, mean age 57.86 ± 8.82, mean T2DM history 5 years), 71 were started on dipeptidyl peptidase-4 inhibitor sitagliptin/saxagliptin, 21 on glucagon-like peptide-1 receptor agonist exenatide, and 46 formed the control group (metformin and sulphonylurea/acarbose)...
August 31, 2023: Diagnostics
keyword
keyword
15054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.